CHA₂DS₂‑VASc and CHA₂DS₂‑VA Scoring for Anticoagulation in Atrial Fibrillation
The 2024 ESC guidelines now use the simplified CHA₂DS₂‑VA score (removing the female sex point), and you should prescribe oral anticoagulation for all patients with a score ≥2, consider it for score of 1, and withhold it for score of 0. 1
Updated Scoring System: CHA₂DS₂‑VA (2024)
The CHA₂DS₂‑VA score replaces CHA₂DS₂‑VASc by eliminating the female sex criterion, creating a 0–8 point scale instead of 0–9. 2, 1 This change reflects contemporary evidence showing decreased stroke risk associated with female sex in recent years. 3
Point Assignment
2 points each for:
- Age ≥75 years
- Prior stroke/TIA/thromboembolism 1
1 point each for:
- Congestive heart failure or LV dysfunction
- Hypertension
- Diabetes mellitus
- Vascular disease (prior MI, PAD, aortic plaque)
- Age 65–74 years 1
Anticoagulation Recommendations by Score
Score 0: No Anticoagulation (Class III)
Do not prescribe oral anticoagulation. 1 These truly low-risk patients have an annual stroke rate of 0.04% and derive no net clinical benefit from anticoagulation. 1, 4 Real-world data confirm stroke rates of 0.64%/year in untreated patients with score 0, with no improved outcomes from antiplatelet or anticoagulant therapy. 4
Score 1: Consider Anticoagulation (Class IIa)
You should consider oral anticoagulation after discussing risks and benefits with the patient. 2, 1 The annual stroke rate is 0.55% with CHA₂DS₂‑VASc score 1, but actual rates vary by which risk factor is present—ranging from 1.96%/year for vascular disease to 3.50%/year for age 65–74. 5 Given that most patients with score 1 have stroke rates exceeding the 1% threshold that justifies anticoagulation, treatment is generally warranted. 6, 5
Score ≥2: Anticoagulation Recommended (Class I)
Prescribe oral anticoagulation. 2, 1 Annual stroke rates range from 0.83% (score 2) to 7.78% (score 8), clearly exceeding the threshold for net benefit from anticoagulation. 1
Choice of Anticoagulant
Direct Oral Anticoagulants (DOACs) Are Preferred
Prescribe a DOAC rather than warfarin as first-line therapy (Class I recommendation). 1 The four preferred agents are apixaban, dabigatran, edoxaban, and rivaroxaban. 1
Standard DOAC Dosing
- Apixaban: 5 mg twice daily; reduce to 2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL 1
- Rivaroxaban: 20 mg once daily with largest meal; reduce to 15 mg once daily if CrCl 15–50 mL/min 1
- Edoxaban: 60 mg once daily; reduce to 30 mg once daily if CrCl 15–50 mL/min 1
- Dabigatran: 150 mg twice daily; reduce to 75 mg twice daily if CrCl 15–30 mL/min 1
When to Use Warfarin Instead
Reserve warfarin for patients with mechanical heart valves or moderate-to-severe mitral stenosis, as DOACs are contraindicated in these populations. 1
What NOT to Do
Never Use Antiplatelet Therapy Alone
Do not prescribe aspirin or aspirin plus clopidogrel as an alternative to oral anticoagulation for stroke prevention (Class III recommendation). 2, 1 Antiplatelet agents are ineffective for stroke prevention in atrial fibrillation and should not be used. 2
Special Populations Requiring Anticoagulation Regardless of Score
Prescribe oral anticoagulation to all patients with atrial fibrillation and hypertrophic cardiomyopathy, regardless of CHA₂DS₂‑VA score (Class I). 2, 1
Prescribe oral anticoagulation to all patients with atrial fibrillation and cardiac amyloidosis, regardless of CHA₂DS₂‑VA score (Class I). 2, 1
Ongoing Management
Reassess thromboembolic risk at every clinical encounter because risk factors evolve over time and patients may transition from low- to high-risk categories requiring anticoagulation initiation. 2, 1 This periodic reassessment is a Class I recommendation. 2
Clinical Pitfalls to Avoid
The CHA₂DS₂‑VA score components carry unequal weight—age 65–74 years confers the highest actual stroke risk despite being worth only 1 point. 5 When counseling patients with score 1, specify which risk factor they have, as this substantially affects their true stroke risk (1.96%–3.50%/year). 5
For subclinical atrial fibrillation detected by devices, anticoagulation decisions are more nuanced. In patients with CHA₂DS₂‑VASc >4, apixaban prevents 1.28 strokes per 100 patient-years while causing 0.68 major bleeds—a clear net benefit. 7 For CHA₂DS₂‑VASc <4, the benefit-to-risk ratio is unfavorable. 7